Journal: Blood
This study developed an allogeneic matched donor CD19 CAR product (CAR-DLI) for adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who relapsed after allogeneic stem-cell transplantation.
Fourteen patients received CAR-DLI infusions, either alone or following lymphodepleting chemotherapy (LD) with fludarabine and cyclophosphamide.
The combination of CAR-DLI with LD significantly improved:
- CAR-DLI engraftment, expansion, and persistence
- 12-month event-free survival
- Overall survival
These benefits were observed compared to CAR-DLI alone, without increasing immunotoxicity or causing significant graft-versus-host disease.
Repeat CAR-DLI dosing after relapse showed minimal benefit.
Overall, CAR-DLI with lymphodepletion demonstrated a favorable safety profile and superior efficacy in this high-risk patient population.